Skip to main content
SpringerLink
Log in

The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Although, guidelines for the appropriate use of enoxaparin are published, yet the extent of their implementation in clinical practice is still questionable. Furthermore, the optimal dosing of enoxaparin in special populations such as renal insufficiency and obesity remains controversial. In the Middle East, there are insufficient data on the appropriateness of enoxaparin use in different indications. Objective (1) To assess the appropriateness of enoxaparin dosing and duration per indication in compliance with the recommended guidelines and their impact on safety and efficacy outcomes in Lebanese health care centers. (2) To evaluate the influence of the hospital type (teaching vs. non-teaching) on the extent of compliance with established guidelines. Setting Seventeen health care centers in Lebanon, including teaching and non-teaching hospitals. Methods An observational, cross-sectional, multicenter study was conducted in 17 Lebanese hospitals. Data on demographics, indication, dosing regimen and clinical outcomes were collected. The appropriateness of dosing practices was determined as per the ACCP guidelines and the FDA dosing recommendations. Main outcome measure The appropriateness of enoxaparin dosing was compared across different hospital type and among special populations including severe renal insufficiency and very obese patients. Results Of the 463 patients who participated in the study, 40% received improper enoxaparin dosing, which was mostly observed in the VTE prophylaxis group (41.6%, P < 0.001). When comparing the overall dosing practices in Lebanese hospitals, there was no statistically significant difference in the correctness of enoxaparin dosing between teaching and non-teaching hospitals (61.6% vs. 58.2%, P = 0.449), respectively. Only 11.5% of renally impaired patients and 59.4% of obese patients received correct doses. Conclusion This study highlighted the improper practice and thus the need of implementation of clinical practice guidelines for the dosing of enoxaparin, in Lebanese hospitals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cohen M, Demers C, Gurfinkel E, Turpie A, Fromell G, Goodman S, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337(7):447–52.

    Article  PubMed  CAS  Google Scholar 

  2. Blazing M, de Lemos J, White H, Fox K, Verheugt F, Ardissino D, et al. Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. A randomized controlled trial. JAMA. 2004;292(10):55–64.

    Article  PubMed  CAS  Google Scholar 

  3. Ferguson J, Califf R, Antman E, Cohen M, Grines C, Goodman S, et al. Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy. JAMA. 2004;292(1):45–54.

    Article  PubMed  CAS  Google Scholar 

  4. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight-heparin compared with intravenous heparin for treatment of pulmonary embolism. Ann Intern Med. 2004;140(3):175–83.

    PubMed  CAS  Google Scholar 

  5. Merli G, Spiro T, Olsson C, Abildgaard U, Davidson B, Eldor A, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous heparin for the treatment of venous thromboembolic disease. Ann Intern Med. 2001;134(3):191–202.

    PubMed  CAS  Google Scholar 

  6. Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? Thromb Res. 2000;100(2):V113–20.

    Article  PubMed  CAS  Google Scholar 

  7. Hirsh J, Warkentin T, Raschke R, Granger C, Ohman E, Dalen J. Heparin and low-molecular-weight heparin. Chest. 1999;115(6):489–510.

    Google Scholar 

  8. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(21):688–98.

    PubMed  CAS  Google Scholar 

  9. Hirsh J, Bauer K, Donati M, Gould M, Samama M, Weitz J. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):141S–59S.

    Article  PubMed  CAS  Google Scholar 

  10. Geerts W, Bergqvist D, Pineo G, Heit J, Samama C, Lassen M, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):381S–453S.

    Article  PubMed  CAS  Google Scholar 

  11. Kearon C, Kahn S, Agnelli G, Goldhaber S, Raskob G, Comerota A. Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):454S–545S.

    Article  PubMed  CAS  Google Scholar 

  12. Harrington R, Becker R, Cannon C, Gutterman D, Lincoff A, Popma J, et al. Antithrombotic therapy for non ST segment elevation acute coronary syndromes: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133(6):670S–707S.

    Article  PubMed  CAS  Google Scholar 

  13. Sanofi-Aventis US LLC. Lovenox® (enoxaparin sodium injection) prescribing information. Bridgewater: Sanofi-Aventis US LLC; 2008.

    Google Scholar 

  14. Chopard P, Dörffler-Melly J, Hess U, Wuillemin W, Hayoz D, Gallino A, et al. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med. 2005;257(4):352–7.

    Article  PubMed  CAS  Google Scholar 

  15. Becker R, Spencer F, Gibson M, Rush J, Sanderink G, Murphy S, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST elevation acute coronary syndromes. Am Heart J. 2002;143(5):753–9.

    Article  PubMed  CAS  Google Scholar 

  16. Mahe I, Gouin-Thibalt I, Drouet L, Simoneau G, Di Castillo H, Siguret V, et al. Elderly medical patients created with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging. 2007;24:63–71.

    Article  PubMed  CAS  Google Scholar 

  17. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673–84.

    PubMed  CAS  Google Scholar 

  18. Montalescot G, Collet J, Tanguy M, Ankri A, Payot L, Dumaine R, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004;110(4):392–8.

    Article  PubMed  CAS  Google Scholar 

  19. Turpie A. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in medical patients with enoxaparin (medenox) Trial. Am J Cardiol. 2000;86:48–52.

    Article  Google Scholar 

  20. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215–31.

    Article  PubMed  CAS  Google Scholar 

  21. Sanderink G, Le Liboux A, Jariwala N, Harding N, Ozoux M, Shukla U, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308–18.

    Article  PubMed  CAS  Google Scholar 

  22. Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116(1):41–50.

    Article  PubMed  CAS  Google Scholar 

  23. Wilson S, Wilbur K, Burton E, Anderson D. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis. 2001;31(1):42–8.

    PubMed  CAS  Google Scholar 

  24. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular weight heparins in special populations. Pharmacotherapy. 2001;21(2):218–34.

    Article  PubMed  CAS  Google Scholar 

  25. Kucher N, Leizorovicz A, Vaitkus P, Cohen A, Turpie A, Olsson C, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005;165(3):341–5.

    Article  PubMed  CAS  Google Scholar 

  26. Rondina M, Wheeler M, Rodgers G, Draper L, Pendleton R. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res. 2010;125(3):220–3.

    Article  PubMed  CAS  Google Scholar 

  27. Vats V, Nutescu E, Theobald J, Wojtynek J, Schumock G. Survey of hospitals for guidelines, policies, and protocols for anticoagulants. Am J Health Syst Pharm. 2007;64(11):1203–8.

    Article  PubMed  Google Scholar 

  28. World Health Organization. Report of a WHO consultation on obesity: preventing and managing the global epidemic. Geneva: World Health Organization; 1998.

    Google Scholar 

  29. Cockcroft DW, Gault MN. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

    Article  PubMed  CAS  Google Scholar 

  30. Macie C, Forbes L, Foster G, Douketis J. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest. 2004;125(5):1616–21.

    Article  PubMed  Google Scholar 

  31. Al-Sallami H, Jordan S, Ferguson R, Medlicott N, Schollum J, Duffull S. Current enoxaparin dosing guidelines have dubious credibility. N Z Med J. 2010;123(1313):62–7.

    PubMed  Google Scholar 

  32. Taher AT, Aoun J, Salameh P. The AVAIL ME study: a multinational survey of VTE risk and prophylaxis. J Thromb Thrombolysis. 2011;31(1):47–56.

    Article  PubMed  Google Scholar 

  33. Rothberg M, Lahti M, Pekow P, Lindenauer P. Venous thromboembolism prophylaxis among medical patients at US hospitals. J Gen Intern Med. 2010;25(6):489–94.

    Article  PubMed  Google Scholar 

  34. Masroujeh R, Shamseddeen W, Isma’eel H, Otrock Z, Khalil I, Taher A, et al. Underutilization of venous thromboembolism prophylaxis in medical patients in a tertiary care center. J Thromb Thrombolysis. 2008;26(2):138–41.

    Article  PubMed  Google Scholar 

  35. Tincani E, Crowther M, Turrini F, Prisco D. Prevention and treatment of venous thromboembolism in the elderly population. Clin Interv Aging. 2007;2(2):237–46.

    PubMed  CAS  Google Scholar 

  36. Spicer K, Gibson P, Bloe C, Cross S, Leslie S, et al. Weight assessment in cardiac patients: implications for prescription of low molecular weight heparin. Postgrad Med J. 2009;85(1001):124–7.

    Article  PubMed  CAS  Google Scholar 

  37. Scholten D, Hoedema R, Scholten S. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002;12(1):19–24.

    Article  PubMed  Google Scholar 

  38. Ellis M, Hadari R, Tchuvrero N, Shapira S, Kovlenko I, Kozmiakova M, et al. Hemorrhagic complications in patients treated with anticoagulant doses of low molecular weight heparin (enoxaparin) in routine hospital practice. Clin Appl Thromb Hemost. 2006;12(2):199–204.

    Article  PubMed  CAS  Google Scholar 

  39. Nieto J, Solano R, Ruiz-Ribo M, Ruiz-Gimenez N, Prandoni P, Kearon C, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. Thromb Haemostasis. 2010;8(6):1216–22.

    Article  CAS  Google Scholar 

  40. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMT 11A. J Am Coll Cardiol. 1997;29(7):1474–82.

    Article  Google Scholar 

  41. Gouin-Thibalt I, Pautas E, Siguret V. Safety profiles of different low molecular weight heparins used at therapeutic dose. Drug Saf. 2005;28(4):333–49.

    Article  Google Scholar 

  42. Al-Sallami H, Barras M, Green B, Duffull S. Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clin Pharmacokinet. 2010;49(9):567–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

No funding was received.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. School of Pharmacy, Pharmacy Practice Department, Lebanese American University, P.O. Box 36, Mail Box: F 74, Byblos, Lebanon

    A. A. Zeitoun

  2. School of Pharmacy, Pharmacy Practice Department, Lebanese American University, P.O. Box 36, Byblos, Lebanon

    J. G. Nassif

  3. School of Pharmacy, Lebanese American University, P.O. Box 36, Byblos, Lebanon

    M. M. Zeineddine

Authors
  1. A. A. Zeitoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. G. Nassif
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. M. Zeineddine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. A. Zeitoun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zeitoun, A.A., Nassif, J.G. & Zeineddine, M.M. The appropriateness of enoxaparin use in Lebanese hospitals: a quality evaluation study. Int J Clin Pharm 33, 934–941 (2011). https://doi.org/10.1007/s11096-011-9559-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-011-9559-1

Keywords

Search

Navigation